Form 4: Phio Pharmaceuticals Director Acquires 10,000 Shares of Common Stock

Robert L. Ferrara, a director of Phio Pharmaceuticals Corp., acquired 10,000 shares of common stock on September 11, 2024, through a restricted stock unit grant.

Summary

• On September 11, 2024, Robert L. Ferrara, a director of Phio Pharmaceuticals Corp., acquired 10,000 shares of common stock.
• The acquisition was made through a restricted stock unit grant, with the shares vesting in one year on the first anniversary.
• Following the transaction, Ferrara beneficially owns 10,000 shares, including those underlying unvested restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing. The sentiment is neutral as it simply reports a transaction.

Positives

• The acquisition of shares by a director may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's increased stake in the company.

Key Dates

Keywords

Phio Pharmaceuticals, Director, Robert L. Ferrara, Stock Acquisition, Restricted Stock Units, Beneficial Ownership, Form 4